BHCM
ARQT icon

Brevan Howard Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Brevan Howard Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,201
Closed -$475K – 1774
2025
Q3 		$475K Sell
25,201
-18,733
-43% -$295K 0.01% 1317
2025
Q2 		$616K Buy
43,934
+3,316
+8% +$46.5K 0.01% 1264
2025
Q1 		$635K Buy
+40,618
New +$572K 0.02% 659
2024
Q4 		– Sell
-35,147
Closed -$327K – 1032
2024
Q3 		$327K Sell
35,147
-52,683
-60% -$520K 0.02% 817
2024
Q2 		$817K Buy
+87,830
New +$794K 0.05% 437
2024
Q1 		– Sell
-51,442
Closed -$166K – 1005
2023
Q4 		$166K Buy
+51,442
New +$140K 0.02% 904

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return